32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
Series A expected to advance lead asset Mucosal-Immune Modulator CS-0003 through Phase II in GI surgical site infections and expand a differentiated GI mucosal-immune pipeline and metabolomics-driven discovery platform NORTH CHICAGO, Ill.–(BUSINESS WIRE)–32 Biosciences, a…